Keywords: fen-phem, charges, gouge, wyeth, results, despite, reporting
Fen-phem charges gouge Wyeth results
Article | 07 February 2005
Despite reporting a healthy rise in sales of 7.0% to $4.60 billion and 10.0% to $17.40 billion for the fourth quarter and full-year 2004, Wyeth ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
